Journal of Affective Disorders, Год журнала: 2024, Номер 367, С. 164 - 173
Опубликована: Авг. 30, 2024
Persons with Major Depressive Disorder (MDD), notably treatment-resistant depression (TRD), are differentially affected by type 2 diabetes mellitus and associated morbidity. Ketamine is highly efficacious in the treatment of adults living MDD, TRD. Herein, we sought to determine effect ketamine on metabolic parameters animal stress paradigms human studies.
Язык: Английский
Expert Opinion on Drug Safety, Год журнала: 2024, Номер 23(5), С. 539 - 542
Опубликована: Март 23, 2024
KEYWORDS: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)liraglutidesemaglutidetirzepatideweight lossobesityoverweightdiabetesdepressionsuicide
Язык: Английский
Процитировано
16
Expert Opinion on Pharmacotherapy, Год журнала: 2024, Номер 25(4), С. 467 - 476
Опубликована: Март 3, 2024
Introduction We systematically reviewed extant studies evaluating the efficacy and tolerability of xanomeline xanomeline-trospium (KarXT) for treatment adults with schizophrenia.
Язык: Английский
Процитировано
8
Physiology & Behavior, Год журнала: 2024, Номер 283, С. 114622 - 114622
Опубликована: Июнь 28, 2024
The roles of metabolic signals, including Glucagon-like peptide 1 (GLP-1), have been implicated in multiple domains outside regulation. There is a growing interest repurposing receptor agonists (GLP-1RAs) as therapeutics for motivation and reward-related behavioural disturbances. Herein, we aim to systematically review the extant evidence on potential effects GLP-1RAs reward system.
Язык: Английский
Процитировано
8
The Journal of Clinical Psychiatry, Год журнала: 2024, Номер 85(2)
Опубликована: Июнь 3, 2024
Язык: Английский
Процитировано
6
European Neuropsychopharmacology, Год журнала: 2024, Номер 85, С. 58 - 65
Опубликована: Июль 1, 2024
In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and being relapse-free through 32 after versus quetiapine extended release (XR) in patients with treatment resistant depression (TRD). Here, we explore time course, burden consequences emergent adverse events (TEAEs) phase IIIb ESCAPE‑TRD trial. Patients TRD were randomised 1:1 to NS or XR, dosed per label alongside an ongoing selective serotonin reuptake inhibitor/serotonin norepinephrine inhibitor. this secondary publication, safety analyses (comprising who received ≥1 dose study treatment) included incidence, severity durations (Kaplan‑Meier method) TEAEs, subsequent dispositional changes. P values not adjusted for multiple testing. 336 340 XR; 334 treatment, respectively. TEAEs more common than XR (91.9 % 78.0 %; p < 0.001), but typically mild/moderate transient nature: a greater proportion resolved on same-day (92.0 12.1 %) lead discontinuation fewer (4.2 11.0 %, respectively; 0.001). The days spent was lower (median: 11.9 21.3 Although frequent NS, mild, less likely XR. Data consistent established profiles, no new signals identified. Alongside efficacy, demonstrably favourable tolerability profile further supports its use TRD.
Язык: Английский
Процитировано
5
CNS Drugs, Год журнала: 2024, Номер 38(9), С. 697 - 718
Опубликована: Авг. 3, 2024
Язык: Английский
Процитировано
5
Journal of Affective Disorders, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
5
Schizophrenia Bulletin, Год журнала: 2024, Номер unknown
Опубликована: Дек. 9, 2024
Overweight and obesity are highly prevalent in people with severe mental illness (SMI). Antipsychotic-induced weight gain (AIWG) is one of the most commonly reported distressing side effects treatment living SMI place a high value on avoidance this effect. Metformin effective pharmacological intervention studied for prevention AIWG yet clear guidelines lacking evidence has not translated into practice. The aim research was to develop guideline use metformin AIWG.
Язык: Английский
Процитировано
5
Der Nervenarzt, Год журнала: 2025, Номер unknown
Опубликована: Янв. 8, 2025
Процитировано
0
FOCUS The Journal of Lifelong Learning in Psychiatry, Год журнала: 2025, Номер 23(1), С. 49 - 52
Опубликована: Янв. 1, 2025
Процитировано
0